KDR and hepatocellular carcinoma: The anti–vascular endothelial growth factor receptor 2 (VEGFR2) antibody ramucirumab has shown promise in unresectable HCC with high serum alpha-fetoprotein (AFP) levels, but its efficacy after Atezolizumab/Bevacizumab is unclear.